Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor-T (CAR-T) cell therapies have revolutionized B cell lymphoma treatment since their market introduction in 2017.
• Despite initial successes, approximately 50% of patients experience relapsed/refractory disease after conventional CAR-T therapy.
• Understanding refractoriness mechanisms is crucial for advancing CAR-T efficacy.

Purpose of the Study:

• To review mechanisms of primary and secondary refractoriness to single-targeting CAR-T therapies in B cell lymphomas.
• To explore challenges associated with current CAR constructs.
• To discuss the potential of multi-antigen targeting strategies, including bivalent and bicistronic CARs, for next-generation therapies.

Main Methods:

• Review of current literature and clinical trial data (Phase 1 and 2) on CAR-T therapies for B cell lymphomas.
• Analysis of synthetic immunobiology advances informing multi-antigen CAR design.
• Discussion of mechanisms underlying CAR-T refractoriness.

Main Results:

• Conventional single-targeting CAR-T therapies exhibit limitations, with about half of patients developing resistance.
• Bivalent and bicistronic CAR constructs represent promising next-generation approaches for adaptable multi-antigen targeting.
• Ongoing clinical trials are evaluating the efficacy and safety of these advanced CAR designs.

Conclusions:

• Multi-antigen targeting strategies are essential for overcoming refractoriness and improving durable responses in B cell lymphomas.
• Optimizing CAR construct architecture, expanding targetable antigens, and enhancing scalability are key to successful translational development.
• Next-generation CAR-T therapies hold significant potential to enhance patient outcomes in the coming years.